Cyclosporin C2 and C0 concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors

Journal of Heart and Lung Transplantation

Volumn 22, Issue 7, 2003, Pages 715-722

  Ray, John E ^a,b   Keogh, Anne M ^b   McLachlan, Andrew J ^c   Akhlaghi, Fatemah ^d  

^a Dept of Clin Pharmacol/Toxicology   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYCLOSPORIN C; DILTIAZEM; KETOCONAZOLE; PROTEIN SUBUNIT;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; EVALUATION; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; IMMUNOASSAY; INFORMATION PROCESSING; LONG TERM CARE; METABOLIC INHIBITION; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECIPIENT; STEADY STATE;

EID: 0037489574     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)00649-6     Document Type: Article

References (30)

1. Lindholm A., Kahan B.D. Influence of cyclosporin pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 54:1993;205-218.
2. Dumont R.J., Ensom M.H.H. Methods of clinical monitoring of cyclosporin in transplant patients. Clin Pharmacokinet. 38:2000;427-447.
3. Kahan B.D., Welsh M., Urbauer D.L., et al. Low intraindividual variability of cyclosporin A exposure reduces chronic rejection and health care costs. J Am Soc Nephrol. 11:2000;1122-1131.
4. Keown P., Kahan B.D., Johnson A., et al. Optimisation of cyclosporin therapy with new therapeutic drug monitoring strategies report from the international Neoral TDM advisory consensus meeting . Transplant Proc. 30:1998;1645-1649.
5. Belitsky P., Dunn S., Johnston A., Levy G. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. Clin Pharmacokinet. 39:2000;117-125.
6. Cole E.H. Neoral monitoring limitations of trough level monitoring and the potential role of limited sampling strategies . Transplant Proc. 32:2000;1556-1558.
7. Trull A., Steel L., Sharples L., Stewart S., et al. Randomised, trough blood cyclosporin concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. Ther Drug Monit. 21:1999;17-26.
8. Steimer W. Performance and specificity of monoclonal immunoassays for cyclosporin monitoring how specific is specific? Clin Chem. 45:1999;371-381.
9. Holt W., Johnston A., Kahan B.D., Morris R.G., et al. New approaches to cyclosporin monitoring raise further concerns about analytical techniques. Clin Chem. 46:2000;872-874.
10. Foradori A., Mezzano S., Videla C., Pefaur J., Elberg A. Modification of the pharmacokinetics of cyclosporin A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazole in stable adult kidney transplants. Transplant Proc. 30:1998;1685-1687.
11. Schroeder J.S., Gao S.Z., Alderman E.L., Hunt S.A., et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med. 328:1993;164-170.
12. Akhlaghi F., Keogh A.M., McLachlan A.J., Kaan A. Pharmacokinetics of cyclosporin in heart transplant recipients receiving metabolic inhibitors. J Heart Lung Transplant. 20:2001;431-438.
13. Gomez D.Y., Wacher V.J., Tomlanovich S.J., Hebert M.F., et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporin. Clin Pharm Ther. 58:1995;15-19.
14. Schroeder T.J., Sridhar N., Pesce A.J., Alexander W., et al. Clinical correlation of cyclosporin-specific and non-specific assays in stable renal transplants, acute rejection, and cyclosporin nephrotoxicity. Ther Drug Monit. 15:1993;190-194.
15. Mahalati K., Belitsky P., Sketris I., West K., et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation. 68:1999;55-62.
16. Grant D., Kneteman N., Tchervenkov J., Roy A., Murphy G., et al. Peak cyclosporin levels (Cmax) correlate with freedom from graft rejection results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8) . Transplantation. 67:1999;1133-1137.
17. Kahan B.D. High variability of drug exposure a biopharmaceutical risk factor for chronic rejection . Transplant Proc. 30:1998;1639-1641.
18. Klauser R., Irschik H., Kletzmayr J., et al. Pharmacokinetic cyclosporin A profiles under long-term Neoral treatment in renal transplant recipients does fat intake still matter . Transplant Proc. 29:1997;3137-3140.
19. Ioannides-Demos L.L., Christophidis N., Ryan P., Angelis P., Liolios L., McLean A.J. Dosing implications of a clinical interaction between grapefruit juice and cyclosporin and metabolite concentrations in patients with autoimmune diseases. J Rheumatol. 24:1997;49-54.
20. Kesten S., Scavuzzo M., Chaparro C., et al. Pharmacokinetic profile and variability of cyclosporin versus Neoral in patients with cystic fibrosis after lung transplantation. Pharmacotherapy. 18:1998;847-850.
21. Mezzano S., Flores C., Ardiles L., Foradori A., Elberg A. Study of Neoral kinetics in adult renal transplantation treated with diltiazem. Transplant Proc. 30:1998;1660-1662.
22. Pollak R., Wong R.L., Chang C.T. Cyclosporin bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Ther Drug Monit. 21:1999;661-663.
23. Preuner J.G., Lehle K., Eichinger H., Rupprecht L. First-pass metabolism of cyclosporin A in human intestine inhibition by diltiazem . Transplant Proc. 30:1998;2545-2546.
24. Cantarovich M., Besner J.-G., Barkum J.S., Elstein E., Loertscher R. Two-hour cyclosporin level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant. 12:1998;243-249.
25. Parke J., Charles B. NONMEN population pharmacokinetic modeling of orally administered cyclosporin from routine drug monitoring data after heart transplantation. Ther Drug Monit. 20:1998;284-293.
26. Halloran P. New strategies for therapeutic drug monitoring of Neoral. Rashid A. Proceedings of a meeting of the First International Advisory Board meeting. 1998;15 Blackwell, Vancouver, BC. Oxford, UK.
27. Lee K.L., Lee K.T., Chung H.M., Lin Y.P. Estimation of mean relative bioavailability of cyclosporin Sandimmune and Neoral using NONMEN in renal transplant recipients. Transplant Proc. 30:1998;3526-3529.
28. Ducharme M.P., Verret L., Brouillette D., Sirois G. Ability of first-pass pharmacokinetic model to characterize cyclosporin blood concentrations after administrations of Sandimmune or Neoral formulations. Ther Drug Monit. 20:1998;165-171.
29. Molden E., Christensen H., Sund R.B. Extensive metabolism of diltiazem and p-glycoprotein-mediated efflux of desacetyldiltiazem (M1) by rat jejunum in vitro. Drug Metab Dispos. 28:2000;107-109.
30. Ku Y.i-Min, Min D., Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporin and its metabolites in healthy volunteers does the formulation difference matter? J Clin Pharmacol. 38:1998;959-965.